Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Phathom Pharmaceuticals, Inc.

NASDAQ: PHAT · Life Sciences · 5 alerts · CIK 1783183

Share price
$5.88Close, Nov 16
Market cap
$478M
Shares outstanding
81.29MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Phathom Pharmaceuticals, Inc. filings on SEC EDGAR ↗

6:02 AM ET 8-K
Court & Legal Update

Phathom Pharmaceuticals Court & Legal Update

Phathom Pharmaceuticals announced that the FDA has opened a public docket to solicit comments regarding legal challenges brought by BDR Pharmaceuticals against the FDA's decision to grant VOQUEZNA 10 years of New Chemical Entity (NCE) exclusivity. The litigation challenges the exclusivity period that currently protects VOQUEZNA through May 2032, and a second potential generic filer, Saba Ilac Sanayii Ve Ticaret AS, has also indicated intent to join the legal challenge.

Counterparty
BDR Pharmaceuticals, Intl. Pvt. Ltd.
5:01 PM ET 8-K
Court & Legal Update

Phathom Pharmaceuticals Court & Legal Update

BDR Pharmaceuticals has filed a lawsuit against the FDA challenging the agency's decision to grant Phathom's VOQUEZNA (vonoprazan) 10 years of NCE exclusivity through May 2032. BDR alleges the FDA improperly applied the GAIN Act to extend this exclusivity, which currently prevents the FDA from receiving abbreviated new drug applications (ANDAs) for generic versions of the drug. Phathom intends to take action to protect its statutory exclusivities and believes the FDA's prior ruling was correct.

Counterparty
BDR Pharmaceuticals International Pvt. Ltd.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.